Drug Database
Back to search

United States· US:50881-007_a32bcaac-6cd8-41be-8686-3e10268e0539

OPZELURA

A ruxolitinib product containing ruxolitinib phosphate, registered in United States by Incyte Corporation. The same ATC class is registered in 14 of our 19 countries.

ATC D11AH09US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedOPZELURAATCD11AH09REGISTER NO.US:50881-007_a32bcaac…PACKS LISTED8CHECKEDJuly 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ruxolitinib phosphateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ruxolitinib is registered in 14 of 19 countries.

Countries holding a registration under ATC D11AH09 (ruxolitinib), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose
Search ruxolitinib products by name

Ruxolitinib · ATC D11AH09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
RUXOLITINIB PHOSPHATE
Manufacturer
Incyte Corporation
Country
United States (US)
ATC code
D11AH09
ATC class
Ruxolitinib
Defined daily dose
30 mg, T
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 12, 2026

Packs & prices · 8

  • ndc11
    50881-007-04
  • ndc11
    50881-007-05
  • ndc11
    50881-007-07
  • ndc11
    50881-007-14
  • ndc11
    5088100704
    1 TUBE in 1 CARTON (50881-007-04) / 5 g in 1 TUBE
  • ndc11
    5088100705
    1 TUBE in 1 CARTON (50881-007-05) / 60 g in 1 TUBE
  • ndc11
    5088100707
    1 TUBE in 1 CARTON (50881-007-07) / 100 g in 1 TUBE
  • ndc11
    5088100714
    1 TUBE in 1 CARTON (50881-007-14) / 3 g in 1 TUBE

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ruxolitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ruxolitinib products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Polink, Ruxib
  • Bulgaria · Руджави, Руксолитиниб Сандоз
  • Cyprus · Ruxolitinib Sandoz
  • Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
  • Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
  • Estonia · Ruxolitinib Msn
  • Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
  • Finland · Ruxolitinib Orion
  • France · Ruxolitinib Biogaran, Ruxolitinib Olpha
  • United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
  • Greece · Jakulya
  • Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
  • Hungary · Ruxolitinib Sandoz
  • Iceland · Jakavi, Jakulya
  • Italy · Ruxolitinib Vivanta
  • Liechtenstein · Jakavi, Opzelura
  • Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
  • Latvia · Ruxolitinib Msn
  • Malta · Donlize, Ruxolitinib Medichem
  • Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
  • Norway · Jakavi, Opzelura
  • Romania · Ruxolitinib Msn
  • Sweden · Ruxolitinib Devatis, Ruxolitinib Orion

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c1e0e754-1b22-499c-b1dc-13956a3546d4
GET /v1/drugs/c1e0e754-1b22-499c-b1dc-13956a3546d4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "TOPICAL",
  "source": "ndc",
  "strength": "15",
  "substance": "RUXOLITINIB PHOSPHATE",
  "productndc": "50881-007",
  "dosage_form": "CREAM",
  "dea_schedule": null,
  "strength_unit": "mg/g",
  "application_number": "NDA215309",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about ruxolitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console